文献速递白血病淋巴瘤

大颗粒淋巴细胞白血病319例回顾性研究

Large granular lymphocytic leukemia - A retrospective study of 319 cases.
PubMed 文献 · Am J Hematol · 2021-04-24

该回顾性研究纳入2001至2020年间就诊于癌症中心的319例大颗粒淋巴细胞白血病(LGLL)患者,其中T-LGLL 295例、慢性NK细胞淋巴增殖性疾病(CLPD-NK)24例。57%患者需要治疗,甲氨蝶呤、环磷酰胺和环孢素A最常用且应答率相似(61.5%-74.4%),环磷酰胺完全缓解率更高(32.3%)。血小板减少是生存更差的独立危险因素。

要点

  • 57%的LGLL患者需要治疗,甲氨蝶呤、环磷酰胺和环孢素A是常用一线选择。
  • 环磷酰胺完全缓解率(32.3%)高于甲氨蝶呤(15.7%)和环孢素A(23.1%)。
  • 血小板减少是LGLL患者生存更差的独立危险因素。

核心结论

  • LGLL患者中57%需要治疗,甲氨蝶呤、环磷酰胺和环孢素A应答率相似,环磷酰胺完全缓解率更高。
  • 血小板减少是LGLL患者生存更差的独立危险因素。

研究设计与样本

  • 回顾性队列研究,纳入2001至2020年间就诊于癌症中心的319例连续LGLL患者。
  • 纳入T-LGLL 295例和慢性NK细胞淋巴增殖性疾病(CLPD-NK)24例,中位年龄65岁(范围17-90岁)。

主要发现

  • 57%的患者需要治疗,甲氨蝶呤、环磷酰胺和环孢素A最常用,应答率在61.5%-74.4%之间。
  • 环磷酰胺完全缓解率为32.3%,高于甲氨蝶呤的15.7%和环孢素A的23.1%。
  • 血小板减少、脾肿大和女性性别(控制自身免疫性疾病后)与甲氨蝶呤、环孢素A或环磷酰胺应答率降低相关。
  • 自身免疫性疾病与应答率升高相关,血小板减少是生存更差的独立危险因素。

临床怎么用

  • LGLL治疗可选用甲氨蝶呤、环磷酰胺或环孢素A,环磷酰胺可能获得更高的完全缓解率。
  • 合并血小板减少、脾肿大或女性患者对甲氨蝶呤、环孢素A或环磷酰胺的应答率可能较低。
  • 合并自身免疫性疾病可能与更高的治疗应答率相关。
  • 血小板减少提示预后较差,应作为风险分层参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Large granular lymphocytic leukemia (LGLL) is a rare hematological malignancy that arises from cytotoxic T lymphocytes (T-LGLL) in 85% of cases and natural killer (NK) cells in the rest. A significant knowledge gap exists regarding the pathogenesis, treatment choices, and prognostic factors of LGLL. We report a cohort of 319 consecutive LGLL patients who presented to our cancer center between 2001 and 2020. A total of 295 patients with T-LGLL and 24 with chronic NK-cell lymphoproliferative disorder (CLPD-NK) were identified. The median age was 65 years (range, 17-90 years). Eighty-three patients (26.0%) had autoimmune diseases. A total of 119 patients (37.3%) had coexisting malignancies, 66 (20.7%) had solid tumors, and 59 (18.5%) had hematological malignancies. Most coexisting malignancies were diagnosed before the diagnosis of LGLL. Treatment was needed for 57% of patients. Methotrexate (MTX), cyclophosphamide (Cy), and cyclosporine A (CSA) were most used and had similar response rates between 61.5%-74.4%. Cy produced more complete responses (32.3%) compared to MTX and CSA (15.7% and 23.1%, respectively). Thrombocytopenia, splenomegaly, and female gender (after controlling for autoimmune diseases) were associated with decreased response rates to MTX, CSA, or Cy. Autoimmune diseases were associated with increased response rates. Thrombocytopenia was an independent risk factor for worse survival.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Dong N, Castillo Tokumori F, Isenalumhe L, et al. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021. PMID: 33819354. doi:10.1002/ajh.26183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。